SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla shares rallied as investors positioned themselves ahead of the company's invite-only Cybercab launch event in Austin, leading to intense debate over whether the stock is primed for a 'buy the rumor, sell the news' pullback or further gains driven by the autonomous vehicle strategy.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing heavy selling pressure following disappointing second-quarter results and a significant downward revision to full-year guidance, with traders expressing concerns over slowing demand and increased competition. The community is sharply divided between those viewing the price drop as an overreaction and potential buying opportunity and those who believe the brand has lost its market relevance and pricing power.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing high volatility as traders react to a mixed earnings report that featured a revenue beat and raised guidance alongside investor concerns regarding slowing growth and AI adoption. While some community members view the dip as a strategic buying opportunity driven by institutional manipulation, others remain skeptical, citing valuation worries and a lack of clear momentum in agentic AI products.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is experiencing high volatility as traders react to a strong quarterly earnings beat and raised full-year guidance, though some investors remain concerned about slowing high-value customer growth and conservative fiscal outlooks. Market sentiment is polarized, with some investors viewing the stock as undervalued and a prime acquisition candidate while others express frustration over recent price underperformance relative to cybersecurity peers.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following a "double beat" in its fiscal second-quarter report, where the company exceeded analyst estimates for both revenue and earnings. While the immediate catalyst was the strong financial performance, sentiment is mixed as traders weigh the positive results against a softer-than-expected third-quarter revenue guidance, which management attributed to contract timing.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

The discussion remains fragmented as traders debate the impact of the company's upsized share repurchase program, with bulls viewing it as a sign of management's confidence and undervaluation, while bears argue it masks ongoing financial and governance concerns. Sentiment is mixed, characterized by persistent debate over the stock's long-term potential versus concerns regarding its OTC status and historical volatility.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending following positive fiscal second-quarter earnings that topped consensus estimates for EPS and revenue, alongside an increased annual recurring revenue outlook driven by its Intelligent Agreement Management (IAM) platform. While some traders view the results as a catalyst for a sustained recovery, others remain skeptical, citing concerns about competition from free alternatives and questioning if the stock's valuation is sustainable.

Samsara, Inc. develops internet connected sensor systems. It combines plug-and-play sensors, wireless connectivity, and cloud-hosted software integrated for deployment. The company was founded by John Bicket and Sanjit Biswas in 2015 and is headquartered in San Francisco, CA.

Samsara Inc - Ordinary Shares - Class A

Samsara Inc

Samsara shares are trending following a third-quarter earnings report that beat analyst expectations for both revenue and profit, driven by strong large-customer adoption and growth in its connected operations platform. While the results prompted several analysts to raise their price targets, traders are debating the company's long-term growth trajectory and the sustainability of its valuation.

Victoria's Secret & Co. operates as a lingerie, clothing and beauty retailer. It offers bras, panties, lingerie, sleepwear, apparel, sport and swim apparel, and beauty products. The company was founded in 1963 and is headquartered in Reynoldsburg, OH.

Victoria`s Secret & Co

Victoria's Secret shares experienced a significant decline following second-quarter results that fell slightly short of Wall Street's elevated sales expectations, despite the company reporting an earnings beat and raising its full-year outlook. While the sharp selloff highlights concerns over weakening sequential growth, some retail traders are viewing the pullback as a potential buying opportunity.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors react to the company's withdrawn proposal for a $500 million stock offering, coupled with significant open-market insider purchases by the Co-CEOs. The community sentiment remains divided between concerns over dilution and enthusiasm for the company's clinical pipeline, specifically the upcoming FDA PDUFA date for its cancer treatment, ivonescimab.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus 

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?

Key PointsCathie Wood continues adding shares of Beam Therapeutics...

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.

Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case

Prime Medicine won arbitration with Beam Therapeutics over PM647, avoiding damages and keeping its AATD gene-editing program on track.read more...

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

Equity

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency falls within its rights under a 2019 collaboration agreement with Beam Therapeutics. 


BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.

Beam Therapeutics Stock Soars 21% in Three Months: Here's Why

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Beam Therapeutics Inc

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.15	--	--	N/A
Q2 '26	-$1.11	-$1.18	-6.66%	MISSED
Q1 '26	-$1.03	-$0.91	11.46%	BEAT
Q4 '25	-$0.94	$2.33	348.45%	BEAT
Q3 '25	-$1.04	-$1.10	-5.99%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

BEAM Earnings

Upcoming Earnings: Q3 '26

Historical Earnings